50years reviews on psychiatry

To celebrate their 50 years, BNA has a huge number of reviews covering 'past, present, future' of many topics in neuroscience. Here is the link to a webpage with list of all published reviews.
Link: https://journals.sagepub.com/bna/past-present-future

There are three reviews on psychiatric drugs and disorders. I list them below

1. Topic: Antipsychotic drugs
   Ref: Cunningham Owens, David, and Eve C. Johnstone. "The development of antipsychotic drugs." Brain and Neuroscience Advances 2 (2018): 2398212818817498.
   Link: https://journals.sagepub.com/doi/full/10.1177/2398212818817498
2. Topic: Psychopharmacology
   Ref: Robinson, Emma. "Psychopharmacology: From serendipitous discoveries to rationale design, but what next?." Brain and Neuroscience Advances 2 (2018): 2398212818812629.
   Link: https://journals.sagepub.com/doi/full/10.1177/2398212818812629
3. Topic: Genetics
   Bray, Nicholas J., and Michael C. O’Donovan. "The genetics of neuropsychiatric disorders." Brain and neuroscience advances 2 (2018): 2398212818799271.
   Link: https://journals.sagepub.com/doi/full/10.1177/2398212818799271

From the review on "the development of antipsychotic drugs" [1] I quote this 

No independent, quality studies have been able to validate the concept of ‘atypical’. so the evidence is irrefutable – excepting clozapine, any Extra-Pyramidal-Symptoms (EPS) advantage attributable to newer antipsychotics can be explained entirely by the fact that new drugs are utilised more prudently than older ones (Geddes et al., 2000; Owens, 2014).

 However these references are either old (Geddes) or not primary (Owens 2014 is a book). So the appeal to 'irrefutable' evidence for a null claim is pretty unconvincing.